Selected article for: "cc NC ND International license and survival group"
Author: Yue-qiang Fu; Yue-lin Sun; Si-wei Lu; Yang Yang; Yi Wang; Feng Xu
Title: Impact of blood analysis and immune function on the prognosis of patients with COVID-19
  • Document date: 2020_4_22
    • ID: a822exap_46
    Snippet: [9] on patients with COVID-19 showed that the lymphocyte count continued to decrease with progression, unto death. The latest researches showed that the severe COVID-19 cases had significantly lower lymphocyte counts compared with non-severe COVID-19 cases [8] [9] [10] [11] [12] [13] . The present study also determined that more than half of the patients (53/85, 62.35%) had lower lymphocyte count than the lower limitation of normal, especially in.....
    Document: [9] on patients with COVID-19 showed that the lymphocyte count continued to decrease with progression, unto death. The latest researches showed that the severe COVID-19 cases had significantly lower lymphocyte counts compared with non-severe COVID-19 cases [8] [9] [10] [11] [12] [13] . The present study also determined that more than half of the patients (53/85, 62.35%) had lower lymphocyte count than the lower limitation of normal, especially in those who died (12/14, 85 .7%). And we found that the lymphocyte counts in dead group were significantly lower than those in survival group. It is not clear whether there are other mechanisms for lymphocyte decline in COVID-19, other than the destruction of lymphoid organs by viral attack. Lymphopenia in patients with SARS before hormone . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cc NC ND International license and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cc NC ND International license and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • cc NC ND International license and SARS patient: 1, 2
    • dead group and lymphocyte count: 1
    • International license and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • International license and lymphocyte decline: 1
    • International license and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • International license and SARS patient: 1, 2
    • late research and present study: 1
    • low limitation and present study: 1, 2, 3
    • lymphocyte count and non severe case: 1, 2
    • lymphocyte count and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lymphocyte count and SARS patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • patient half and present study: 1, 2
    • present study and progression decrease: 1, 2